Business Overview

Operating Status
Jan 2011
Business Model
Offering Type
Founded in 2011, NovellusDX has brought together a team of skilled individuals from several fields, including synthetic biology, functional genomics, bioinformatics, engineering, algorithm development, clinical laboratory and healthcare commercialization. Together, they lead the companys mission to deliver evidence-based clinical insights and enable oncology professionals to treat every cancer and each patient with the precise treatment and to support pharmaceutical companies with their drugs life cycle.Genome sequencing techniques reveal mutations but provide no knowledge whether the translated protein is actually aberrantly activated. This is because the functional significance of most mutations is unknown, let alone that of networks of interacting proteins. NovellusDx leverages its live cell based assay to complement the power of NGS with actionable insights on the affected signaling pathways.


Board Members and Advisors

Head, Corporate New Ventures and Board Member

Funding Rounds

Total Funding


Funding Rounds
Series C
Last Funding Series

Date Announced

Funding Round

Amount Raised


AI Technology Stack™

AI Team Size
AI Technologies
AI Description
AI Technologies
AI Algorithms
AI Hardware

© 2021 All rights reserved.

You cannot copy content of this page

Sign up for free

  • Save profiles to your list
  • Basic search functionality

Sign up to keep browsing

You reached your pageview limit

  • Save profiles to your list
  • Basic search functionality
  • Browse our leading AI database